Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 ...
Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell ...
DIA's Europe Annual Meeting, featuring discussions from top European health leaders, will be held March 18-20 in Basel.
C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...
C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to obtain a Drug Establishment License (DEL) to produce life-saving cell therapies ...
Stockholm, Sweden Saturday, February 22, 2025, 09:00 Hrs [IST] ...
With authorization from the European Medicines Agency (EMA) to manufacture cell therapies for the European market, C3i positions itself on the global biotechnology stage as Canada's pre-eminent ...
Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...
The European Medicines Agency (EMA) has unveiled a pilot scheme for 'adaptive licensing' in which innovative new drugs will be released to patients before they have been given final regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results